About 2.5 million persons in the US had hepatitis C between 2017 and 2020.1 Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) on management of hepatitis C virus (HCV) infection were updated in 2023.2
GENOTYPE PREVALENCE — About 70-75% of HCV infections in the US are caused by HCV genotype 1 (~50% are caused by genotype 1a), and about 20-25% are caused by genotype 2 or 3. HCV genotype 3 is associated with faster disease progression and increased rates of...
- In Brief: Subcutaneous Ocrelizumab (Ocrevus Zunovo) for Multiple Sclerosis
- In Brief: FluMist Influenza Vaccine for Self-Administration
- COVID-19 Update: Novavax Vaccine for 2024-2025
- Figure 1: Treatment of Hepatitis C Virus Infection in Treatment-Naive Adults (online only)
- Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)
- Lazertinib (Lazcluze) for Non-Small Cell Lung Cancer (online only)
- Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine
- An Epinephrine Nasal Spray (neffy) for Anaphylaxis
- Vonoprazan (Voquezna) for Nonerosive GERD
- A New RSV Vaccine (mResvia) for Adults ≥60 Years Old
- In Brief: New Warning for Fezolinetant (Veozah)
- Figure 1: Pneumococcal Vaccine Recommendations for Adults 19-64 Years Old (online only)
- Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old (online only)
- Addendum: Effectiveness of mRNA COVID-19 Vaccines (online only)
- In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma (online only)
- In Brief: Erzofri — Another Once-Monthly Paliperidone Formulation (online only)
RELEASE
The FDA has approved Crexont (Amneal), an extended-release capsule formulation of carbidopa/levodopa, for treatment of Parkinson's disease (PD), postencephalitic parkinsonism, and parkinsonism associated with carbon monoxide or manganese intoxication. Crexont contains a combination of immediate-release carbidopa/levodopa granules and extended-release levodopa pellets. An extended-release carbidopa/levodopa oral capsule (Rytary) has been available from the same manufacturer for years; the patent for Rytary expires in 2025.1
LEVODOPA/CARBIDOPA ― The combination of levodopa and carbidopa is the most effective treatment for the motor symptoms of PD. Immediate-release carbidopa/levodopa produces a consistent response lasting 5-6 hours for the first 2-5 years of treatment, but over time the duration of benefit …